Why Moderna Is Rising (Again) Today
Moderna (NASDAQ: MRNA) is starting the week on a strong note, with the company's shares climbing by 9.2% as of 11:25 a.m. on Monday. Since Moderna did not release any company-specific news, we can safely assume that investors continue to be optimistic that the biotech company will make a fortune off of its investigational COVID-19 vaccine, mRNA-1273.
Moderna announced some exciting news regarding mRNA-1273 last week. First, the company received clearance from the U.S. Food and Drug Administration (FDA) to move forward with a phase 2 study for the coronavirus vaccine; Moderna should start this study very soon. Second, the company is already planning to start a phase 3 clinical trial for mRNA-1273 in early summer.
Image Source: Getty Images.
Source Fool.com
